Omeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Omeros Corporation (NASDAQ:OMER)’s share price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $8.21 and traded as high as $12.14. Omeros shares last traded at $11.69, with a volume of 790,665 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright boosted their target price on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Stock Up 2.2%

The firm has a 50-day simple moving average of $12.29 and a 200 day simple moving average of $8.21. The company has a market cap of $828.82 million, a price-to-earnings ratio of -5.79 and a beta of 2.45.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.39. As a group, research analysts expect that Omeros Corporation will post -3.09 EPS for the current year.

Insider Buying and Selling

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming purchased a new position in shares of Omeros in the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Omeros during the fourth quarter worth $33,000. Arax Advisory Partners lifted its holdings in shares of Omeros by 56.4% during the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 1,894 shares during the period. Farther Finance Advisors LLC grew its position in Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 5,677 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.